// App-Quantinova.ai

: POTENTIAL IMPACT OF THE 2017 ACC/AHA HIGH BLOOD PRESSURE GUIDELINE IN NORMOTENSIVE PATIENTS WITH STABLE CORONARY ARTERY DISEASE ( INSIGHTS FROM THE CLARIFY REGISTRY )

Researchers

Presenter

  • Vidal-Petiot, E

Principal Investigators

  • Sorbets, E

  • Bhatt, D

  • Ducrocq, G

  • Elbez, Y

  • Ferrari, R

  • Ford, I

  • Tardif, J.-C

  • Tendera, M

  • Fox, K

  • Steg, P.G

Medical Centers

  • AP-HP, Hospital Bichat, Physiology Department, Paris, FRANCE

  • AP-HP, Hospital Avicenne, Cardiology Department, Paris, FRANCE

  • Brigham & Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, MA, USA

  • AP-HP, Hospital Bichat, Cardiology Department and FACT, French Alliance for Cardiovascular Trials, Paris, FRANCE

  • AP-HP, FACT, French Alliance for Cardiovascular Trials, Paris, FRANCE

  • Department of Cardiology and LTTA Centre, University of Ferrara, Cotignola, ITALY

  • University of Glasgow, Immunology, Glasgow, UNITED KINGDOM

  • Montreal Heart Institute, Universite Montreal, Montreal, QC, Canada

  • Medical University of Silesia , Katowice,Polen

  • National Heart and Lung Institute, Imperial College, Institute of Cardiovascular Medicine and Science, Royal Brompton Ho, London, UNITED KINGDOM

Locations

  • France

  • United States

  • Italy

  • United Kingdom

  • Canada

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • Acetyl-CoA carboxylase

  • GC Vitamin D Binding Protein

  • Sex hormone binding globulin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved